Composite preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV

A compound preparation, H3N2 technology, applied in the direction of medical preparations containing active ingredients, antiviral agents, organic active ingredients, etc., can solve the problems of side effects, inability to stop drug at will, reduce damage, improve autoimmune system, slow down speed effect

Inactive Publication Date: 2021-01-26
朱洪滨
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The purpose of the present invention is to solve the existing antiviral drugs in the prior art, which have certain side effects and cannot be withdrawn at will, and propose a compound that can effectively inhibit HIV, HBV, H1N1, H3N2 and nCoV Preparation, briefly describe the technical effect achieved under

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV
  • Composite preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV
  • Composite preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Experimental purpose: to determine the inhibition of the compound preparation on HBV.

[0032] Subjects: 12 patients, including 6 male patients and 6 female patients, aged between 30 and 35, all of them are hepatitis B virus carriers.

[0033] The patient's condition: the value of hepatitis B virus DNA is 9.09E+2, the hepatitis B surface antigen is greater than 0.2ng / ml, the hepatitis B surface antibody is 460-480IU / L, the hepatitis B e antigen is 0.6-0.7PEIU / mL, and the hepatitis B e antibody is 1.02 -1.1PEIU / mL, hepatitis B core antibody is 1.3-1.5PEIU / mL, median of liver stiffness (KPA) is 13.3-13.4, median of fat decay (db / m) is 265-295, color Doppler ultrasound result is normal .

[0034] Experimental method: 3 male patients, male No. 1, male No. 2 and male No. 3, and 3 female patients, female No. 1, female No. 2 and female No. 3, were selected to take the compound preparation respectively for a period of 8 months. The unselected 3 male patients, male No. 4, male...

Embodiment 2

[0047] Experimental purpose: To determine the inhibition of the compound preparation on nCoV.

[0048] Experimental objects: 12 pigs were selected, of which 6 were adult boars and 6 were juvenile boars, all infected with the novel coronavirus (nCoV).

[0049] Experimental method: Select adult boar No. 1, adult boar No. 2, adult boar No. 3, juvenile boar No. 1, juvenile boar No. 2 and juvenile boar No. 3 to take the compound preparation, adult boar No. 4 , No. 5 adult boar, No. 6 adult boar, No. 4 juvenile boar, No. 5 juvenile boar and No. 6 juvenile boar did not take the compound preparation, but carried out the same feeding, and the survival of 12 pigs To record, the recording period is 10 days, and the records are shown in the following table:

[0050]

[0051]

[0052]As can be seen from the above table, the compound preparation can inhibit nCoV.

[0053] Principle of work of the present invention and use process:

[0054] In the present invention, the compound pre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of biotechnologies, and particularly relates to a composite preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV. The composite preparation comprises the following components in parts by mass: 8-12 parts of nicotinamide mononucleotide, 2-6 parts of chlorogenic acid, 2-6 parts of echinacea purpurea extract and 1-3 parts of glutathione. The composite preparation can effectively inhibit HIV, HBV, H1N1, H3N2 and nCoV, effectively improve the autoimmune system, and can be discontinued at any time. Moreover, the composite preparation has no side effect, and does not cause replication activity of HIV, HBV, H1N1, H3N2 or nCoV after discontinuation, thereby reducing damage to organs of the body, and decelerating the deterioration of diseases.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a composite preparation that can effectively inhibit HIV, HBV, H1N1, H3N2 and nCoV. Background technique [0002] AIDS is the abbreviation of Acquired Immunodeficiency Syndrome, which is a chronic infectious disease caused by Human Immunodeficiency Virus (HIV). The disease is mainly transmitted through sexual contact, blood and mother to child. HIV mainly invades and destroys CD4+ T lymphocytes, resulting in impairment or even defect of immune cells and (or) functions of the body, and eventually merges with various serious opportunistic infections and tumors. It has the characteristics of rapid spread, slow onset and high fatality rate. [0003] Hepatitis B virus is called hepatitis B virus for short. It is a DNA virus belonging to the family Hepadnaviridae. According to current knowledge, HBV is only susceptible to humans and orangutans, causing viral hepatitis B disease. The w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/06A61P31/18A61P31/20A61P31/16A61P31/14A61K31/706A61K31/216A61K36/28
CPCA61K31/216A61K31/706A61K36/28A61K38/06A61P31/14A61P31/16A61P31/18A61P31/20A61K2300/00
Inventor 朱洪滨盛晓春徐俊
Owner 朱洪滨
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap